Under Lock and Key
Orphan drug designations enable companies to cut R&D costs and secure market exclusivity.
Dr Kei Enomoto at RGC Jenkins & Co outlines the incentives and questions whether extra intellectual property protection is needed.
Dr Kei Enomoto, RGC Jenkins & Co (September 2013)
Keywords: Orphan Drug Regulation